These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28380027)

  • 1. Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.
    Pang KH; Rosario DJ; Morgan SL; Catto JW
    PLoS One; 2017; 12(4):e0175070. PubMed ID: 28380027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA.
    Drayton RM; Rehman I; Clarke R; Zhao Z; Pang K; Miah S; Stoehr R; Hartmann A; Blizard S; Lavin M; Bryant HE; Martens-Uzunova ES; Jenster G; Hamdy FC; Gardiner RA; Catto JW
    Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):268-75. PubMed ID: 25392181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy.
    Nygård Y; Haukaas SA; Halvorsen OJ; Gravdal K; Frugård J; Akslen LA; Beisland C
    BMC Urol; 2016 Jul; 16(1):39. PubMed ID: 27391229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
    Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.
    Neveu B; Jain P; Têtu B; Wu L; Fradet Y; Pouliot F
    Oncotarget; 2016 Jan; 7(2):1300-10. PubMed ID: 26594800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Milillo A; Papotti M; Porpiglia F
    BJU Int; 2014 Dec; 114(6b):E56-E61. PubMed ID: 24472071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Porpiglia F
    Anticancer Res; 2015 Apr; 35(4):2417-22. PubMed ID: 25862908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.
    Hessels D; Klein Gunnewiek JM; van Oort I; Karthaus HF; van Leenders GJ; van Balken B; Kiemeney LA; Witjes JA; Schalken JA
    Eur Urol; 2003 Jul; 44(1):8-15; discussion 15-6. PubMed ID: 12814669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
    Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].
    Vlaeminck-Guillem V; Campos-Fernandes JL; Champetier D; Chikh K; Decaussin-Petrucci M; Devonec M; Gobeaux N; Paparel P; Perrin P; Rodriguez-Lafrasse C; Ruffion A
    Ann Biol Clin (Paris); 2011; 69(1):31-9. PubMed ID: 21463993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
    Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
    Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.